Stocktwits on MSN
Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV
The trial evaluated treatment responses in patients who were virologically suppressed, switching from a multi-tablet regimen ...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The ...
Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...
Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...
Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...
Brian Zanoni, MD, MPH, discusses forecasts that suggest declining global HIV rates but persistent gaps in care and funding.
There are several variants, or clades, of HIV in circulation. The most widely-circulating variant, HIV-1 Clade C, accounts ...
One percent of people infected with HIV have a second line of defense deep in their immune system, which serves as a back-up for the body's defenses that get wiped out by the virus, according to a new ...
Funding to fight HIV among gay and bisexual men and transgender women is a fraction of what it should be, researchers said on Tuesday, with advocates blaming stigma for the shortfall.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback